The algorithm prioritizes Microvascular Decompression (MVD) for de novo classic cases, while favoring SRS or percutaneous routes for MS and high-risk elderly patients.
Treatment Selection Probe
Define the patient's clinical and radiographic profile to obtain an evidence-based surgical recommendation for Trigeminal Neuralgia.
Guidelines & Evidence
Clinical Details
Section 1
When to Use
When to Use
Medically-refractory Trigeminal Neuralgia failing ≥1 sodium channel blocker (Carbamazepine or Oxcarbazepine) at adequate doses.
Informed consent discussion — patients deserve to understand the trade-offs between cure rate, risk, and durability before making a surgical choice.
Section 2
Literature
Development
The surgical treatment algorithm for TN developed iteratively. Walter Dandy first identified the compressing vessel in 1925. Peter Jannetta pioneered the modern MVD technique in the 1960s. Lars Leksell's Gamma Knife enabled radiosurgical ablation in the 1990s. The percutaneous rhizotomies (Hakanson glycerine injection, Sweet's radiofrequency thermocoagulation, Mullan's balloon compression) provided rapid day-case alternatives. Modern practice requires individualising the choice based on patient age, MS status, imaging, and pain phenotype.
Section 3
Pearls/Pitfalls
The Core Trade-off
MVD has the highest long-term cure rate but requires posterior fossa craniotomy under general anaesthesia. Gamma Knife is non-invasive but takes 3-6 months to work, with ~20% developing facial numbness. Percutaneous procedures work immediately but rely on intentionally injuring the nerve, causing variable numbness and anesthesia dolorosa risk in repeated procedures.
Section 4
Evidence Appraisal
Primary Reference
Stereotactic radiosurgery for trigeminal neuralgia: a systematic review
Tuleasca C et al. • J Neurosurg. 2019;130(3):733-757
